Schizophrenia Clinical Trial
Official title:
Evaluation of Metamemory in Patients With Schizophrenia
Verified date | November 2017 |
Source | University Hospital, Clermont-Ferrand |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the respective roles of aging and schizophrenia in
the regulation of metamemory using a generation strategy. 4 groups will be necessary to
comparison:
Adult patients (18-45 years) Adult controls (18-45 years) Aged patients (≥ 59.5 years) Aged
controls (≥ 59.5 years)
The effects of age and the disease could lead to interaction in regulating metamemory. The
effect of age would be aggravated by the disease.
Status | Completed |
Enrollment | 120 |
Est. completion date | May 23, 2016 |
Est. primary completion date | May 23, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - For both: - Age: between 18 and 45 years for adults, and 59.55 and above for older, For patients : - DSM-5 criteria of schizophrenia - Adult patients (<45 years) will be matched to elderly patients (> 59.55 years) gender and educational level, - Patients followed as outpatients, - Age of onset of the disease less than 40 years, - Patients whose disease has stabilized: no changes psychotropic treatment for at least 1 month - Not more of a benzodiazepine, - Patients on protection of justice or not, For controls : - - Matched for sex to patient - Age-matched (+/- 3 years) to patient - Matched for educational level (+/- 2 years) to patients Exclusion Criteria: - -For patients : - Any other comorbid psychiatric diagnosis of Axis I DSM-5 (particularly depression, addiction excluding tobacco, dementia) - Patients with impaired vision or hearing preventing the realization of the tests. - Long-term Anticholinergic treatment. - Patients with less 5 years of school For controls: - Any psychiatric diagnosis according to DSM-5, including addictions (excluding tobacco) - Head injuries, brain injuries or diseases, - vision or hearing problems preventing the realization of the tests. - Current or past addiction to all toxic substances except tobacco. - Long-term Anticholinergic treatment. - Related to the first degree diagnosed with a psychotic disorder |
Country | Name | City | State |
---|---|---|---|
France | CHU Clermont-Ferrand | Clermont-Ferrand |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand | LAPSCO, Psychology University, Blaise Pascal University, Clermont-Ferrand. |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | difference of judgement of learning using a 5 point scale (0%, 25%, 50%, 75%, 100%) using a generation strategy. | the 4 groups of participants formed by the case-control study in two age strata value their judgments of learning for each pair of words using a 5 point scale (0%, 25%, 50%, 75%, 100%) with the generation strategy. | at day 1 | |
Secondary | Difference of judgement of learning using a 5 point scale (0%, 25%, 50%, 75%, 100%) between generation and reading strategies | the 4 groups of participants formed by the case-control study in two age strata, value their judgments of learning for each pair of words using a 5 point scale (0%, 25%, 50%, 75%, 100%) in a generation strategy and in a reading strategy. | at day 1 | |
Secondary | Difference of number of recalled word using a generation strategy | the 4 groups of participants formed by the case-control study in two age strata recalled the word they learn using a generation strategy. | at day 1 | |
Secondary | Difference of number of recalled word between generation and reading strategies | the 4 groups of participants formed by the case-control study in two age strata recalled the word they learn using a generation strategy and a reading strategy. | at day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |